A Deeper Look into New Therapies in the
Management of Sickle Cell Disease: How the Latest Advances May
A continuing medical education
activity provided by NAMCP and AAMCN
New Horizons in the Management of Sickle Cell Disease (SCD):
Leveraging Treatment Breakthroughs to Make Informed Decisions in
Managed Care is a three-part webinar series
This is Part 2 of the series focusing on new therapies in the
management of sickle cell disease
This activity is an archive from the webinar held December 10, 2020
This activity is valid from January 1, 2020 to January 1, 2023
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
Global Blood Therapeutics and Novartis
Sickle cell disease (SCD) is a chronic, life-long, debilitating
disease with many forms that can range in clinical severity from
asymptomatic to life-threatening. In the US, SCD affects an
estimated 90,000 to 100,000 Americans. This disease can lead to the
obstruction of blood vessels, reduced blood flow to vital organs,
and a weakened immune system. Fortunately for patients, novel
therapies have been approved that have shown tremendous benefit in
Upon completion of this
activity, participants will be able to:
Discuss the pathophysiology,
physical manifestations, economic burden, clinical course, and
impact on patient quality of life of sickle cell disease (SCD)
Examine the mechanisms underlying
new and emerging treatments for patients with SCD that work
upstream of sickle hemoglobin (HbS) polymerization and may be
Evaluate the latest clinical
evidence regarding new and emerging disease-modifying options
for patients with SCD and the implications for patients
Analyze the safety and efficacy of
new therapies that manage acute vaso-occlusive pain events in
Examine the latest understanding
regarding SCD phenotypes and implications for treatment
selection and sequencing
Identify patients with vaso-occlusive
pain events in SCD for whom a newer therapy is an appropriate
choice for the next step in the management of their disease
||Ahmar U. Zaidi, MD
Assistant Professor of Pediatrics
Division of Pediatric Hematology/Oncology
Central Michigan University SOM
Children’s Hospital of Michigan
Cooley & Whitten Center for Hemoglobinopathies
has served on advisory boards for Global Blood
Therapeutics and Novartis. He has served as a consultant
for Global Blood Therapeutics, Novartis, Emmaus Life
Sciences, Cyclerion, and bluebird bio. He has received
grants/research support from Global Blood Therapeutics,
Imara, and Emmaus Life Sciences. He serves on the
speaker’s bureau for Global Blood Therapeutics.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by educational grants from
Global Blood Therapeutics and Novartis
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue